loading page

Staged Management of Heparin-Induced Thrombocytopenia for Renal Cavo-Atrial Cancer Removal on Cardiopulmonary Bypass
  • +2
  • Salim Aziz,
  • Shailendra Sharma,
  • Jenna Aziz,
  • James Gould,
  • Xiomara Fernandez
Salim Aziz
The George Washington University Hospital
Author Profile
Shailendra Sharma
The George Washington University Hospital
Author Profile
Jenna Aziz
Howard University College of Medicine
Author Profile
James Gould
The George Washington University Hospital
Author Profile
Xiomara Fernandez
The George Washington University Hospital
Author Profile

Abstract

Management of patients with acute heparin-induced thrombocytopenia (HIT) with cavo-atrial renal cancer requiring surgery on cardiopulmonary bypass (CPB) and possible deep hypothermia circulatory arrest is a challenge. A staged approach using Bivalirudin, plasmapheresis, and intravenous immunoglobulin (IVIG) was used to preoperatively de-escalate HIT guided by enzyme-linked immunosorbent assay (ELISA) and serotonin release assay (SRA). Intraoperatively heparin was used as the anticoagulant for CPB as DHCA was likely to be used to remove the atrio-caval tumor. Heparin is effective in preventing clots in the circuit during DHCA. To prevent HIT upon re-exposure to heparin during CPB, a bolus of a Cangrelor (reversible P2Y12 platelet receptor inhibitor) was given before heparin and during CPB whilst platelet activity was monitored using platelet reactivity units (PRU). Postoperatively, to prevent recurrence of HIT, plasmapheresis was used until SRA and optical density (OD) resulted. The patient had a successful outcome.